News and Events

Thin melanomas a substantial public health burden

4 May 2017

Thin melanomas are a substantial public health burden, despite excellent prognosis, according to an analysis of SEER data in the United States. The authors conclude that “efforts should be made to diagnose melanoma at the in situ stage”.

Combining SRT and immunotherapy

28 April 2017

Patients treated with stereotactic radiotherapy (SRT) and immunotherapy have a higher incidence/risk of intracranial complications, but a longer overall survival, according to authors of this study.

Does pregnancy influence melanoma prognosis?

21 April 2017

Results of this study indicate that pregnancy or post partum [pregnancy-associated melanoma (PAM)] is associated with a worse prognosis than melanoma not related to pregnancy, both in terms of overall survival and disease-free survival, according to its authors. 

Regional radiation therapy impacts outcome for node-positive melanoma

20 April 2017

Regional radiation therapy was associated with a reduced risk of regional recurrence among patients with ECE (extracapsular extension) and clinically detected nodal disease, according to the results of a single institution study.  The authors conclude that “in the era of increasingly effective systemic therapies, the value of improved regional control potentially takes on greater significance”.

Maternal and perinatal outcomes in pregnancy-associated melanoma

19 April 2017

When diagnosed at early stages, melanoma does not seem to alter the evolution of gestation, whereas patients with advanced stages of melanoma frequently deliver prematurely, by caesarean section, with lower neonatal weight, higher neonatal morbidity and mortality rates, according to authors of this study.

Liquid biopsies promising for monitoring patients with melanoma

13 April 2017

Liquid biopsies are a promising area of investigation for improving the clinical monitoring of patients with solid malignancies, such as melanoma, according to authors of this recent study.  The authors conclude that cellfree circulating tumor DNA (ctDNA) quantification might also be a novel biomarker with a prognostic value for melanoma patients.

Molecular and immune differences associated with differential drug responses

13 April 2017

Heterogeneity in mutational and immune profiles within tumours from individual patients could explain differences in treatment response, according to a team of researchers from the University of Texas MD Anderson Cancer Center. The team studied the radiological responses of 60 patients with metastatic melanoma, half of whom received targeted drug therapy and half of whom received an immune checkpoint inhibitor.